A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in the Treatment of Microsatellite Stable Advanced Colorectal Cancer

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06682247

Enrollment

200

Registered

2024-11-12

Start date

2024-11-15

Completion date

2025-12-31

Last updated

2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer Metastatic

Brief summary

This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.

Interventions

DRUGChidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Aged≥18 years 2. Histology-confirmed metastatic CRC (mCRC); 3. ECOG 0\ 2 4. At least one efficacy evaluation 5. Life expectancy of at least 3 months.

Exclusion criteria

1. Lack of follow-up data. 2. Chidamide stopped after less than two cycles. 3. Serious comorbidities that interfere with the efficacy or safety analysis

Design outcomes

Primary

Measure	Time frame
Progression-free survival(PFS)	2 years

Secondary

Measure	Time frame
Objective Response Rate（ORR）	2 years
Clinical Benefit Rate (CBR)	2 years
Disease Control Rate （DCR）	2 years
Overall survival (OS)	2 years

Contacts

Primary Contactfeng wang

wangfeng@sysucc.org.cn020-87343088

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026